AISDC: Automated Imaging Screening and Data Capture

Automated Imaging Screening and Data Capture are important elements of laboratory automation in pharmaceuticals. Data streams from different sources now arrives in several non-standardized formats.  This makes the consideration of the whole data set difficult (often requiring opening five or more applications).  Standardized data solves this issue and allows researchers to compare findings from different sources.

The AISDC project will examine existing standards for MRIs and other medical images and will endeavor as one project element, to develop standards for other images such as plate reader well images, and other related images.

The absence of standards for Imaging Screening and Data Capture in Pharmaceutical Products delivery processes leads to inefficiencies in resource utilization and to longer than necessary product development cycles.

The development of an automated system based on universally accepted standards will improve efficiencies in drug delivery and enable multi-national firms to take full advantage of globally-distributed resources.

The AISDC project is a collaborative effort among SILA, the W6 Consortium, Systems X, and SyBIT.  SiLA and Systems X will engage in collaboration in data interface standardization focused on two areas:  imaging data from microscopy and screening services, logistics interfaces, LIMS Data Exchange Interface, and enterprise data management.

The project will be managed and operated within the framework of SILA and will be consistent with SILA goals and objectives.

1.    Background

SILA is a global initiative to standardize software interfaces in the field of life science research instrumentation.  Instigated by the pharmaceutical industry’s need for flexible laboratory automation, the initiative is now supported by major device and software suppliers worldwide.

The SiLA’s foundation is based on three pillars:  to improve business performance through overall process optimization and data standardization; to foster new device and data integration possibilities and allowing new applications in drug discovery; and to enable lab of the future and lab automation enterprise network opportunities.

In reference to the actual standards in development, SiLA is focused on four areas:  device interface standard, common command sets, labware specification standard and data interface standards.  Within these four areas, work groups are organized to produce results. These work groups include but do not limit to the following general interface, data capture, labware specification, remote monitoring/remote

This project is closely related to other SILA projects which draw on the expertise of device and software suppliers to the pharmaceuticals laboratory automation sector.  Partners in this project are located in Switzerland, Europe and the USA.

The project will build upon work already completed within other projects and the partners by Region can be described as follows:

Switzerland: End user pharmaceutical firm conducting research and development of pharmaceutical products; Device providers developing interoperability standards for equipment and devices used in pharmaceutical laboratory automation;  Software vendors developing specialized laboratory automation software; project management activities.

Europe: Device providers developing interoperability standards for equipment and devices used in pharmaceutical laboratory automation; Software vendors developing specialized laboratory automation software; dissemination of project results.

USA: End user pharmaceutical firm conducting research and development of pharmaceutical products; Device providers developing interoperability standards for equipment and devices used in pharmaceutical laboratory automation; Software vendors developing specialized laboratory automation software; dissemination of project results.

3.   Relationship of the Partners

To promote international cooperation, three (3) or more IMS Regions are required to establish a project. Qualifying partners must be part of a Region represented in the overall IMS Scheme and working on a Manufacturing Technology Project that has been sanctioned by IMS. The IMS International Steering Committee must approve partners outside of an IMS Region.

Potential project partners in this project come from three IMS Regions: Switzerland, Europe and USA. (to be confirmed)

SILA – Project Coordinator (Switzerland)

Systems-X, Novartis, Hoffman – La Roche, Tecan – End Users (Switzerland)

SILA USA, Perkin Elmer, Novartis USA, UCLA, CeuticalSoft, Code Refinery

InfoTeam Software, Pistoia – (Europe)

DOWNLOADS

AISDC Project MTP DRAFT MOA

PLEASE CONTACT YOUR LOCAL MTP PROJECT DEVELOPMENT COACH FOR MORE INFORMATION.